Opinion

Video

The Evolution of ALK+ NSCLC Care

Panelists discuss how they will explore optimizing care for patients with ALK-positive non-small cell lung cancer (ALK+ NSCLC) through treatment selection, sequencing strategies, and interpretation of emerging clinical data.

Panel Introduction

This summary is based on an AJMC Peer Exchange program titled “Advancing ALK+ NSCLC Care: Optimizing Treatment, Sequencing, and Long-Term Outcomes,” featuring the following experts:

  • Ryan Haumschild, PharmD, MS, MBA, CPEL (Moderator) - vice president of Ambulatory Pharmacy at Emory Healthcare and Winship Cancer Institute of Emory University
  • Elizabeth Castronovo, NP - advanced practice provider
  • Martin Dietrich, MD, PhD - oncology specialist
  • Mary Grizzard, MSN, FNP - family nurse practitioner
  • Christine M. Lovly, MD, PhD, FASCO - oncology researcher/physician

Introduction and Treatment Landscape Evolution

  • Dr Haumschild introduced the program focus on ALK+ NSCLC care optimization
  • Dr Lovly posed a question regarding how the treatment landscape has evolved in recent years
  • Panelists established the foundation for discussing advances in ALK-targeted therapies

Program Overview

The panelists explore strategies for optimizing care of patients with ALK-positive non–small cell lung cancer through evidence-based treatment selection, sequencing approaches, and interpretation of emerging clinical data to improve long-term outcomes.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Carla Nester
AJMC interview with Ali Shan Hafeez and Dr Abdul Rafae Faisal | Background image credit: ipopba - stock.adobe.com
2 experts in this video
2 experts in this video
Julia Rotow, MD, Dana-Farber
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo